{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T07:10:27Z","timestamp":1790493027567,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005624","name":"PATH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005624","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The cysteine-rich Pfs48\/45 protein, a <jats:italic>Plasmodium falciparum<\/jats:italic> sexual stage surface protein, has been advancing as a candidate antigen for a transmission-blocking vaccine (TBV) for malaria. However, Pfs48\/45 contains multiple disulfide bonds, that are critical for proper folding and induction of transmission-blocking (TB) antibodies. We have previously shown that R0.6C, a fusion of the 6C domain of Pfs48\/45 and a fragment of PfGLURP (R0), expressed in <jats:italic>Lactococcus lactis<\/jats:italic>, was properly folded and induced transmission-blocking antibodies. Here we describe the process development and technology transfer of a scalable and reproducible process suitable for R0.6C manufacturing under current Good Manufacturing Practices (cGMP). This process resulted in a final purified yield of 25 mg\/L, sufficient for clinical evaluation. A panel of analytical assays for release and stability assessment of R0.6C were developed including HPLC, SDS-PAGE, and immunoblotting with the conformation-dependent TB mAb45.1. Intact mass analysis of R0.6C confirmed the identity of the product including the three disulfide bonds and the absence of post-translational modifications. Multi-Angle Light Scattering (MALS) coupled to size exclusion chromatography (SEC-MALS), further confirmed that R0.6C was monomeric (~70 kDa) in solution. Lastly, preclinical studies demonstrated that the R0.6C Drug Product (adsorbed to Alhydrogel<jats:sup>\u00ae<\/jats:sup>) elicited functional antibodies in small rodents and that adding Matrix-M<jats:sup>\u2122<\/jats:sup> adjuvant further increased the functional response. Here, building upon our past work, we filled the gap between laboratory and manufacturing to ready R0.6C for production under cGMP and eventual clinical evaluation as a malaria TB vaccine.<\/jats:p>","DOI":"10.3389\/fimmu.2020.606266","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T03:28:02Z","timestamp":1610508482000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["A Reproducible and Scalable Process for Manufacturing a Pfs48\/45 Based Plasmodium falciparum Transmission-Blocking Vaccine"],"prefix":"10.3389","volume":"11","author":[{"given":"Susheel K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Plieskatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bishwanath K.","family":"Chourasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Fabra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asier","family":"Garcia-Senosiain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin L\u00f6vgren","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Reimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sauerwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthijs M.","family":"Jore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Theisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"B1","volume-title":"World Malaria Report 2019","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515257","article-title":"Seven-Year Efficacy of RTS,S\/AS01 Malaria Vaccine among Young African Children","volume":"374","author":"Olotu","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1355246","article-title":"The GMZ2 malaria vaccine: from concept to efficacy in humans","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020947","article-title":"Non-apical membrane antigen 1 (AMA1) IgGs from Malian children interfere with functional activity of AMA1 IgGs as judged by growth inhibition assay","volume":"6","author":"Miura","year":"2011","journal-title":"PloS One"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004708","article-title":"Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya","volume":"4","author":"Ogutu","year":"2009","journal-title":"PloS One"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.03.014","article-title":"A randomized controlled phase 2 trial of the blood stage AMA1-C1\/Alhydrogel malaria vaccine in children in Mali","volume":"27","author":"Sagara","year":"2009","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182015001341","article-title":"Naturally acquired immunity to sexual stage P. falciparum parasites","volume":"143","author":"Stone","year":"2016","journal-title":"Parasitology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1276833","article-title":"Towards clinical development of a Pfs48\/45-based transmission blocking malaria vaccine","volume":"16","author":"Theisen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30344-X","article-title":"Safety and immunogenicity of Pfs25H-EPA\/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults","volume":"18","author":"Sagara","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel(R), a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naive Adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PloS One"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.44.100190.002241","article-title":"Sexual differentiation in malaria parasites","volume":"44","author":"Alano","year":"1990","journal-title":"Annu Rev Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00199-4","article-title":"A central role for P48\/45 in malaria parasite male gamete fertility","volume":"104","author":"van Dijk","year":"2001","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.162.5.1460","article-title":"Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito","volume":"162","author":"Vermeulen","year":"1985","journal-title":"J\u00a0Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1017\/S0031182000062065","article-title":"Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes","author":"Ponnudurai","year":"1989","journal-title":"Parasitology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-3024.1990.tb00990.x","article-title":"Properties of epitopes of Pfs 48\/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum","volume":"12","author":"Carter","year":"1990","journal-title":"Parasite Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.158.3.976","article-title":"Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum","volume":"158","author":"Rener","year":"1983","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M700948200","article-title":"Epitope analysis of the malaria surface antigen pfs48\/45 identifies a subdomain that elicits transmission blocking antibodies","volume":"282","author":"Outchkourov","year":"2007","journal-title":"J Biol Chem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.020","article-title":"A multi-stage malaria vaccine candidate targeting both transmission and asexual parasite life-cycle stages","volume":"32","author":"Theisen","year":"2014","journal-title":"Vaccine"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.040","article-title":"A Plasmodium falciparum 48\/45 single epitope R0.6C subunit protein elicits high levels of transmission blocking antibodies","volume":"33","author":"Singh","year":"2015","journal-title":"Vaccine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12934-017-0710-0","article-title":"Construct design, production, and characterization of Plasmodium falciparum 48\/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine","volume":"16","author":"Singh","year":"2017","journal-title":"Microb Cell Fact"},{"key":"B21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12934-018-0902-2","article-title":"Lactococcus lactis provides an efficient platform for production of disulfide-rich recombinant proteins from Plasmodium falciparum","volume":"17","author":"Singh","year":"2018","journal-title":"Microb Cell Fact"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA119.011268","article-title":"The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable","volume":"295","author":"Singh","year":"2020","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.054","article-title":"Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48\/45 based vaccine antigen by SpyTag\/SpyCatcher mediated virus-like display","volume":"35","author":"Singh","year":"2017","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01256","article-title":"Pfs230 and Pfs48\/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum","volume":"10","author":"Singh","year":"2019","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpara.2012.09.002","article-title":"Measuring the blockade of malaria transmission\u2013an analysis of the Standard Membrane Feeding Assay","volume":"42","author":"Churcher","year":"2012","journal-title":"Int J Parasitol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tree.2008.10.008","article-title":"Generalized linear mixed models: a practical guide for ecology and evolution","volume":"24","author":"Bolker","year":"2009","journal-title":"Trends Ecol Evol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.01.039","article-title":"Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice","volume":"31","author":"Magnusson","year":"2013","journal-title":"Vaccine"},{"key":"B28","article-title":"Development of a heterologous geneexpression system for use in Lactococcus lactis","volume-title":"Recombinant Protein Production with Prokaryotic and Eukaryotic Cells","author":"Bredmose","year":"2001"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1475-2859-4-2","article-title":"Protein secretion in Lactococcus lactis : an efficient way to increase the overall heterologous protein production","volume":"4","author":"Le Loir","year":"2005","journal-title":"Microb Cell Fact"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.09.017","article-title":"A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies","volume":"22","author":"Theisen","year":"2004","journal-title":"Vaccine"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw617","article-title":"Naturally Acquired Antibodies Target the Glutamate-Rich Protein on Intact Merozoites and Predict Protection Against Febrile Malaria","volume":"215","author":"Kana","year":"2017","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.03748-14","article-title":"Genome-wide transcriptional responses to carbon starvation in nongrowing Lactococcus lactis","volume":"81","author":"Ercan","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02484-14","article-title":"Molecular and metabolic adaptations of Lactococcus lactis at near-zero growth rates","volume":"81","author":"Ercan","year":"2015","journal-title":"Appl Environ Microbiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00004","article-title":"Comparative Genome Analysis of Lactococcus lactis Indicates Niche Adaptation and Resolves Genotype\/Phenotype Disparity","volume":"10","author":"Wels","year":"2019","journal-title":"Front Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/1574-6968.12351","article-title":"Recombinant protein expression in Lactococcus lactis using the P170 expression system","volume":"351","author":"Jorgensen","year":"2014","journal-title":"FEMS Microbiol Lett"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.02.022","article-title":"A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2\u2013a GLURP-MSP3 fusion protein malaria vaccine candidate","volume":"29","author":"Lousada-Dietrich","year":"2011","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.016","article-title":"Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen","volume":"34","author":"Baldwin","year":"2016","journal-title":"Vaccine"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria","volume":"69","author":"Mordmuller","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1087","article-title":"Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2","volume":"69","author":"Dejon-Agobe","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2013.814822","article-title":"Matrix-M adjuvant: enhancing immune responses by \u2018setting the stage\u2019 for the antigen","volume":"12","author":"Bengtsson","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.12.030","article-title":"Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice","volume":"32","author":"Magnusson","year":"2014","journal-title":"Vaccine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1803554","article-title":"Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine","volume":"378","author":"Shinde","year":"2018","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041451","article-title":"Matrix-M adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen","volume":"7","author":"Reimer","year":"2012","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-8991-x","article-title":"Matrix-M adjuvant enhances immunogenicity of both protein- and modified vaccinia virus Ankara-based influenza vaccines in mice","volume":"66","author":"Magnusson","year":"2018","journal-title":"Immunol Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1159\/000337007","article-title":"Lymph node macrophages","volume":"4","author":"Gray","year":"2012","journal-title":"J Innate Immun"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.06.007","article-title":"B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node","volume":"27","author":"Carrasco","year":"2007","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1673","article-title":"Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine","author":"Shinde","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.606266\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T20:48:06Z","timestamp":1610570886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.606266\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2020.606266"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.606266","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"article-number":"606266"}}